Trial Details

RECRUITING
Basic Information
Clinical ID c572
Identifier NCT06606808
Trial Title Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions Ulcerative Colitis (UC)|Crohn Disease (CD)
Interventions DRUG: Risankizumab-800CW 4.5 mg|DRUG: Risankizumab-800CW 15 mg|DRUG: Risankizumab-800CW 25 mg|DRUG: Risankizumab-800CW optimal dose
Participant Information
Sponsor University Medical Center Groningen
City Groningen
Country/Region Netherlands
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type INTERVENTIONAL
Phase PHASE1|PHASE2
Time Information
Start Date 2024-11-08
Primary Completion Date 2025-08-25
Completion Date 2025-12-25